Woodline Partners’s European Biotech Acquisition Corp. Warrant EBACW Stock Holding History

Woodline Partners’s Portfolio EBACW Stock Details EBACW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-91,666	Closed	-$5K	–	911
2022 Q2	$5K	Hold	91,666	–	–	﹤0.01%	750
2022 Q1	$18K	Hold	91,666	–	–	﹤0.01%	638
2021 Q4	$55K	Hold	91,666	–	–	﹤0.01%	626
2021 Q3	$52K	Hold	91,666	–	–	﹤0.01%	610
2021 Q2	$88K	Buy	+91,666	New	+$85.3K	﹤0.01%	511

Other funds holding EBACW

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

AGC

Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.5% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.4% 1-Year Est. Return

CCM

CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Woodline Partners's EBACW Position: Q3 2022 in Review

Woodline Partners sold out of European Biotech Acquisition Corp. Warrant (EBACW) in Q3 2022, closing a stake of 91,666 shares — an estimated $5K sold.

Woodline Partners first reported a position in EBACW in Q2 2021 and held it in 5 quarters. The position peaked at $88K in Q2 2021. 29 funds tracked by Wall St. Rank hold EBACW as of Q3 2022.

Woodline Partners reported no remaining European Biotech Acquisition Corp. Warrant position as of Q3 2022 after selling out during the quarter.
Woodline Partners sold 91,666 European Biotech Acquisition Corp. Warrant shares in Q3 2022, an estimated $5K.
Woodline Partners first reported a position in European Biotech Acquisition Corp. Warrant in Q2 2021 and held it in 5 quarters.
Woodline Partners's European Biotech Acquisition Corp. Warrant position peaked at $88K in Q2 2021.
29 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Warrant as of Q3 2022.

Based on Woodline Partners's 13F filing for Q3 2022, filed 14 Nov 2022.